Replies to post #53649 on Biotech Values

[DewDiligence]

VRTX – Only one week before the Telaprevir PROVE-1/2 data are to be presented at AASLD, VRTX today disclosed for the first time the existence of a follow-on HCV protease inhibitor. Does anyone think the timing of this disclosure is significant?